Neuroprotective Effects of Brain-Gut Peptides: A Potential Therapy for Parkinson’s Disease

作     者：Dong Dong Junxia Xie Jun Wang 

作者机构：Department of Physiology and Pathophysiology Shandong Provincial Key Laboratory of Pathogenesis and Prevention of Neurological Disorders Shandong Provincial Collaborative Innovation Center for Neurodegenerative Disorders and State Key Disciplines: Physiology Medical College of Qingdao University 

出 版 物：《Neuroscience Bulletin》 (神经科学通报（英文版）)

年 卷 期：2019年第35卷第6期

页      面：1085-1096页

核心收录：

学科分类：081704[工学-应用化学] 07[理学] 08[工学] 0817[工学-化学工程与技术] 070303[理学-有机化学] 0703[理学-化学] 

基　　金：supported by grants from the National Natural Science Foundation of China (31571054 and 81430024)the Excellent Innovative Team of Shandong Province and Taishan Scholars Construction Project  China 

主　　题：Parkinson's disease Glucagon-like peptide 1 Pituitary adenylate cyclase activating polypeptide Nesfatin-1 Ghrelin 

摘      要：Parkinson s disease(PD) is the second most common neurodegenerative disease and is typically associated with progressive motor and non-motor ***, dopamine replacement therapy is mainly used to relieve the motor symptoms, while its long-term application can lead to various complications and does not cure the disease. Numerous studies have demonstrated that many brain-gut peptides have neuroprotective effects in vivo and in vitro, and may be a promising treatment for PD. In recent years, some progress has been made in studies on the neuroprotective effects of some newly-discovered braingut peptides, such as glucagon-like peptide 1, pituitary adenylate cyclase activating polypeptide, nesfatin-1, and ghrelin. However, there is still no systematic review on the neuroprotective effects common to these peptides. Thus,here we review the neuroprotective effects and the associated mechanisms of these four peptides, as well as other brain-gut peptides related to PD, in the hope of providing new ideas for the treatment of PD and related clinical research.